Connect with us

Markets

Mind-Bending Medicine: An Overview of Psychedelic Substances

Published

on

psychedelic medicine research infographic

An Overview of Psychedelic Substances

Fueled by a slew of new research, psychedelics may hold the key to treating a multitude of debilitating disorders such as addiction, PTSD, and depression.

But as an industry that has laid dormant for decades, it will need to shed its negative connotations that have limited its potential and undermined new discoveries for so long.

The infographic above showcases data from The Report on Psychedelics which explains seven of the most common psychedelic substances and examines the many mind-bending ways they could radically transform mental health as we know it.

Resurrecting a Stigmatized Industry

Although evidence of humans using psychedelics as medicine dates back thousands of years, it was not until the 1940s that psychiatrists became advocates of their therapeutic potential.

Unfortunately, recreational psychedelics became a symbol of the 1960’s counterculture movement, which contaminated the industry’s reputation. The U.S. responded by introducing the Controlled Substances Analogue Enforcement Act, deeming these drugs illegal and stymying research studies in the process.

Following some new discoveries in the early ‘90s however, psychedelics moved from the hands of festival-goers back to the labs of scientists. Since then, certain substances such as psilocybin have been granted breakthrough therapy status for treating depression by the U.S. FDA.

With these recent developments, new companies and investment opportunities are beginning to emerge in the psychedelics space. But these complex drugs are not always easy to understand—so let’s dive in.

What are Psychedelics?

Psychedelics are psychoactive substances that can alter perception, mood, and cognitive processes. There are two broad classifications of psychedelics that relate to chemical structure.

  • Entheogenic Plants: Plants or fungi that produce chemical substances that can cause hallucinations
  • Synthetic Drugs: Drugs created in laboratory setting to mimic the effects of entheogenic plants

Here are seven of the most common psychedelic substances explained:

DrugCharacteristicsLegal StatusConditions StudiedNumber of Studies/trials
Ayahuasca (Entheogenic plant)Traditional tea used in religious or spiritual rituals, mainly in South America.Not formally prohibited.Major depression1
DMT (Entheogenic plant)Powerful hallucinogen produced by multiple plants, humans, and animals with an unusually short bioavailability period.U.S.: Schedule I
Canada: Schedule III
UN: Schedule I
UK: Class A
Healthy subjects1
Ibogaine (Entheogenic plant)Derived from the tabernanthe iboga plant, a shrub found in the rainforest of western Africa.U.S.: Schedule I
Canada: Controlled
UN: Uncontrolled
UK: Illegal
Drug dependence, alcoholism2
Psilocybin (Entheogenic plant)Naturally occurring psychedelic chemical found in more than 100 species of mushrooms.U.S: Schedule 1
Canada: Schedule III
UN: Schedule I
UK: Class A
Depression, OCD, anorexia, migraines, cluster headaches, substance abuse40
Ketamine (Synthetic)Commonly used as an anesthetic and administered intravenously (IV) or intramuscularly (IM).U.S.: Schedule III
Canada: Schedule I
UN: Uncontrolled
UK: Class B
Depression, mental health disorders, suicidal ideations, pain and related conditions, healthy subjects925
LSD (Synthetic)First derived from ergot, a fungus that develops on grains such as rye.U.S: Schedule I
Canada: Schedule III
UN: Schedule I
UK: Class A
Cluster headaches, depression, anxiety, chronic pain, Healthy subjects
12
MDMA (Synthetic)Typically associated with rave culture, as it imparts feelings of joy combined with increased energy levels.U.S.: Schedule I
Canada: Schedule I
UN: Schedule I
UK: Class A
PTSD, autism, alcohol use disorder, Healthy subjects
43

To avoid history repeating itself, Johns Hopkins University has created the Center for Psychedelic and Consciousness Research with the aim of enforcing strict standards of scientific rigor for the industry to follow.

On the Precipice of Change

With sound scientific evidence and standards coming into place, it’s no surprise that investors—from bestselling author Tim Ferris to several established cannabis companies—are supporting the born-again industry.

Given the industry’s foothold in recreational use, a therapeutic comeback may be a tough pill for many to swallow. However, it is possible that we are on the precipice of not only a psychedelic revolution but more importantly, a mental health one.

“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy.”

—Stanislav Grof

Click for Comments

Markets

Will Tesla Lose Its Spot in the Magnificent Seven?

We visualize the recent performance of the Magnificent Seven stocks, uncovering a clear divergence between the group’s top and bottom names.

Published

on

Will Tesla Lose Its Spot in the Magnificent Seven?

This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.

In this graphic, we visualize the year-to-date (YTD) performance of the “Magnificent Seven”, a leading group of U.S. tech stocks that gained prominence in 2023 as the replacement of FAANG stocks.

All figures are as of March 12, 2024, and are listed in the table below.

RankCompanyYTD Change (%)
1Nvidia90.8
2Meta44.3
3Amazon16.9
4Microsoft12
5Google0.2
6Apple-6.7
7Tesla-28.5

From these numbers, we can see a clear divergence in performance across the group.

Nvidia and Meta Lead

Nvidia is the main hero of this show, setting new all-time highs seemingly every week. The chipmaker is currently the world’s third most valuable company, with a valuation of around $2.2 trillion. This puts it very close to Apple, which is currently valued at $2.7 trillion.

The second best performer of the Magnificent Seven has been Meta, which recently re-entered the trillion dollar club after falling out of favor in 2022. The company saw a massive one-day gain of $197 billion on Feb 2, 2024.

Apple and Tesla in the Red

Tesla has lost over a quarter of its value YTD as EV hype continues to fizzle out. Other pure play EV stocks like Rivian and Lucid are also down significantly in 2024.

Meanwhile, Apple shares have struggled due to weakening demand for its products in China, as well as the company’s lack of progress in the artificial intelligence (AI) space.

Investors may have also been disappointed to hear that Apple’s electric car project, which started a decade ago, has been scrapped.

Continue Reading

Subscribe

Popular